Literature DB >> 29359613

Eyelid arteriovenous malformation treated with pre-surgical embolization: A case report.

Robert Juszkat1, Bartosz Żabicki1, Katarzyna Stanistawska1, Karolina Szepelak1, Bartosz Kądziołka2, Piotr Sosnowski1, Jarosław Kocięcki3.   

Abstract

Background Arteriovenous malformations are potentially serious vascular anomalies that are rarely encountered in the eyelid and require a multidisciplinary approach. Objectives We would like to describe the technical and clinical aspects related to the treatment of palpebral arteriovenous malformation with selective embolization, followed by surgical resection. Methods A 40-year-old patient presented with an isolated high-flow palpebral arteriovenous malformation. Transarterial embolization, using a liquid embolic agent (PHIL™), was performed in this patient. Results Angiographic and clinical follow-up revealed good results with clinical regression of the mass. Conclusion Although endovascular treatment of palpebral arteriovenous malformations is technically challenging, good functional and cosmetic result was achieved. Arteriovenous malformation embolization using PHIL™ seems to be very effective and makes subsequent surgical procedure safe and feasible. Level IV Evidence obtained from multiple time series with or without the intervention, such as case studies. Dramatic results in uncontrolled trials might also be regarded as this type of evidence.

Entities:  

Keywords:  Arteriovenous malformation; PHIL™; embolization; swollen eyelid; vascular malformation

Mesh:

Year:  2018        PMID: 29359613      PMCID: PMC5967179          DOI: 10.1177/1591019917753711

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  9 in total

Review 1.  Selection of treatment modalities or observation of arteriovenous malformations.

Authors:  John C Barr; Christopher S Ogilvy
Journal:  Neurosurg Clin N Am       Date:  2012-01       Impact factor: 2.509

2.  Preliminary experience with precipitating hydrophobic injectable liquid in brain arteriovenous malformations.

Authors:  Naci Koçer; Hakan Hanımoğlu; Şebnem Batur; Sedat Giray Kandemirli; Osman Kızılkılıç; Zihni Sanus; Büge Öz; Civan Işlak; Mehmet Yaşar Kaynar
Journal:  Diagn Interv Radiol       Date:  2016 Mar-Apr       Impact factor: 2.630

3.  Preliminary experience with the liquid embolic material agent PHIL (Precipitating Hydrophobic Injectable Liquid) in treating cranial and spinal dural arteriovenous fistulas: technical note.

Authors:  Joe J Leyon; Swarupsinh Chavda; Allan Thomas; Saleh Lamin
Journal:  J Neurointerv Surg       Date:  2015-05-20       Impact factor: 5.836

Review 4.  Vascular malformations of the orbit: classification and the role of imaging in diagnosis and treatment strategies*.

Authors:  Jack Rootman; Manraj K S Heran; Douglas A Graeb
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2014 Mar-Apr       Impact factor: 1.746

Review 5.  Transvenous Approach to Intracranial Arteriovenous Malformations: Challenging the Axioms of Arteriovenous Malformation Therapy?

Authors:  Omar Choudhri; Michael E Ivan; Michael T Lawton
Journal:  Neurosurgery       Date:  2015-10       Impact factor: 4.654

6.  Eyelid arteriovenous malformation treated with embolization leading to a branch retinal artery occlusion.

Authors:  Jonathan Shaver
Journal:  Optometry       Date:  2011-10-26

7.  Endovascular treatment of arteriovenous malformation.

Authors:  Robert Juszkat; Bartosz Zabicki; Paweł Checiński; Marcin Gabriel; Nawal Matar
Journal:  Aesthetic Plast Surg       Date:  2008-09-27       Impact factor: 2.326

8.  Absence of skin discoloration after transarterial embolization of a subcutaneous auricular arteriovenous malformation with PHIL.

Authors:  Matthijs In 't Veld; Peter Wa Willems
Journal:  Interv Neuroradiol       Date:  2016-06-12       Impact factor: 1.610

9.  Preliminary experience with Precipitating Hydrophobic Injectable Liquid (PHIL) in treating cerebral AVMs.

Authors:  Edgar A Samaniego; Vladimir Kalousek; German Abdo; Santiago Ortega-Gutierrez
Journal:  J Neurointerv Surg       Date:  2016-01-27       Impact factor: 5.836

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.